يعرض 1 - 20 نتائج من 151 نتيجة بحث عن '"time to treatment failure"', وقت الاستعلام: 0.83s تنقيح النتائج
  1. 1
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal

    المساهمون: Murianni, V., Signori, A., Buti, S., Rebuzzi, S. E., Bimbatti, D., De Giorgi, U., Chiellino, S., Galli, L., Zucali, P. A., Masini, C., Naglieri, E., Procopio, G., Milella, M., Fratino, L., Baldessari, C., Ricotta, R., Mollica, V., Soraru, M., Tudini, M., Prati, V., Malgeri, A., Atzori, F., Di Napoli, M., Caffo, O., Spada, M., Morelli, F., Prati, G., Nole, F., Vignani, F., Cavo, A., Lipari, H., Roviello, G., Catalano, F., Damassi, A., Cremante, M., Rescigno, P., Fornarini, G., Banna, G. L.

    وصف الملف: ELETTRONICO

    Relation: info:eu-repo/semantics/altIdentifier/pmid/38410103; info:eu-repo/semantics/altIdentifier/wos/WOS:001181865000001; volume:14; firstpage:1; lastpage:9; numberofpages:9; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11567/1173336

  6. 6
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
  12. 12
  13. 13
    Academic Journal
  14. 14
  15. 15
  16. 16

    المصدر: Breast, Vol 55, Iss, Pp 63-68 (2021)
    The Breast : Official Journal of the European Society of Mastology

    مصطلحات موضوعية: TTF, time-to-treatment failure, MBC, metastatic breast cancer, Phases of clinical research, DFI, disease-free interval, Gastroenterology, law.invention, 0302 clinical medicine, PR, partial response, Nanoparticle albumin–bound paclitaxel, Randomized controlled trial, Nab-PTX, nanoparticle albumin–bound paclitaxel, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, 030212 general & internal medicine, Chemotherapy-induced peripheral neuropathy, Hazard ratio, CIPN, chemotherapy-induced peripheral neuropathy, General Medicine, Metastatic breast cancer, Solvent-base paclitaxel, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, PFS, progression-free survival, Treatment Outcome, RDI, relative dose intensity, 030220 oncology & carcinogenesis, Toxicity, Original Article, Female, ORR, overall response rate, DCR, disease control rate, medicine.medical_specialty, Paclitaxel, Breast Neoplasms, Nab-paclitaxel, lcsh:RC254-282, TNBC, triple-negative breast cancer, Drug Administration Schedule, PROs/HRQoL, patient-reported outcomes/health-related quality-of-life, ECOG, Eastern Cooperative Oncology Group performance, OS, overall survival, 03 medical and health sciences, Internal medicine, Albumins, medicine, Humans, business.industry, QoL, quality-of-life, CR, complete remission, medicine.disease, RECIST, response evaluation criteria in solid tumors, HR, hazard ratio, Confidence interval, CI, confidence interval, sb-PTX, comparing solvent-based paclitaxel, Surgery, business

  17. 17

    المصدر: Cancer Medicine
    Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
    Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717

    وصف الملف: Print-Electronic

  18. 18
  19. 19
  20. 20